Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Regorafenib Plus Ipilimumab and Nivolumab Shows Intriguing Activity in MSS mCRC

November 8th 2022

Regorafenib plus ipilimumab and nivolumab led to encouraging survival and responses in approximately half of patients with microsatellite stable, non–liver metastatic colorectal cancer who progressed on prior chemotherapy.

Investigators Highlight Top Advances at ESMO 2022

November 7th 2022

Data presented at the ESMO Congress 2022 highlighted advances across treatment modalities, including landmark data for trials in melanoma, breast cancer, and lung cancer, as well as early data that made headlines in a subgroup of patients with colon cancer.

Dr. Barzi on the Need for More Sensitive MRD Testing in CRC

November 3rd 2022

Afsaneh Barzi, MD, PhD, discusses the need for more sensitive minimal residual disease testing in colorectal cancer.

Dr. Klempner on the Unique Trial Design of KRYSTAL-1 in CRC

November 2nd 2022

Sam Klempner, MD, discusses the design and eligibility criteria of the ongoing phase 1/2 KRYSTAL-1 trial in colorectal cancer.

CRC Tumor Sidedness Plays an Increasing Role in Clinical Practice

October 31st 2022

Prognosis, treatment outcomes, and molecular characteristics have become associated with sidedness in colorectal cancers making the distinction an essential characteristic for consideration in decison-making.

Genomic Testing and ctDNA Add to Personalized Treatment Approach in Metastatic CRC

October 29th 2022

Benjamin Adam Weinberg, MD, discussed the expanding role of circulating tumor DNA in CRC and the various testing methods, the utilization of liquid biopsies, and the need for up-front genetic testing to identify molecular alterations.

MOUNTAINEER Data Confirm Clinical Benefit of Tucatinib Plus Trastuzumab in HER2+ mCRC

October 28th 2022

Additional analyses of the phase 2 MOUNTAINEER trial further support the early administration of tucatinib in combination with trastuzumab as an optimal treatment strategy for patients with previously treated HER2-positive metastatic colorectal cancer.

Dr. Cohen on the Use of ctDNA for Chemotherapy Decisions in CRC

October 26th 2022

Stacey A. Cohen, MD, discusses the evaluation of the role of circulating tumor DNA to determine the benefit of chemotherapy in colorectal cancer.

ctDNA Helps Predict Recurrence in Real-World Analysis of Patients With Resected CRC

October 21st 2022

Stacey A. Cohen, MD, discusses the results of real-world analysis of patients with resected stage I-III colorectal cancer, how circulating tumor DNA status correlated with recurrence rates, and how these real-world data compared with previous observational studies.

177Lu-FAP-2286 Displays Preliminary Antitumor Activity in Advanced or Metastatic Solid Tumors

October 18th 2022

Lutetium-177-FAP-2286 produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase 1/2 LuMIERE trial.

Dr. Strickler on the Benefit of Combining Tucatinib With Trastuzumab in HER2+ CRC

October 14th 2022

John H. Strickler, MD, discusses the benefit of combining tucatinib with trastuzumab in HER2-positive metastatic colorectal cancer.

CAR T-cell Therapy CYAD-101 No Longer Under Development for Metastatic CRC

October 14th 2022

Celyad Oncology has discontinued development its investigational CAR T-cell therapy CYAD-101 for the treatment of patients with unresectable metastatic colorectal cancer.

Dr. Dasari on the Investigation of Fruquintinib in mCRC

October 6th 2022

Nageshwara Arvind Dasari, MD, discusses the patient population observed in the phase 3 FRESCO-2 trial in metastatic colorectal cancer.

Dr. Strickler on the Importance of Targeted Therapies in HER2+ mCRC

October 5th 2022

John H. Strickler, MD, discusses the importance of investigating targeted therapies in HER2-positive metastatic colorectal cancer.

Tucatinib plus trastuzumab in patients (pts) with HER2-Positive Metastatic Colorectal Cancer (mCRC): Patient Reported Outcomes from MOUNTAINEER

October 5th 2022

Dr Hubbard reviews patient reported outcomes from the MOUNTAINEER trial, which evaluated the combination of tucatinib plus trastuzumab in patients with HER2-positive metastatic colorectal cancer.

SCO-101 Plus FOLFIRI Will Continue to Be Studied Despite Missing Primary End Point in mCRC

October 4th 2022

The addition of SCO-101 to FOLFIRI chemotherapy was safe and tolerable but failed to elicit a greater than 30% reduction in tumor volume in patients with metastatic colorectal cancer, though study of the combination will continue.

Fruquintinib Provides Significant Survival Benefits in Heavily Pretreated mCRC

September 26th 2022

Nageshwara Arvind Dasari, MD, discusses the results of the phase 3 FRESCO-2 trial of fruquintinib in patients with refractory metastatic colorectal cancer, the significance of the data for the treatment paradigm, and the potential next steps for examining the agent in this disease.

Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer (HER2+ mCRC): A Systematic Literature Review and Meta-Analysis of Clinical Outcomes

September 23rd 2022

Dr. Tanios Bekaii-Saab discusses the results of a systematic review/meta-analysis intended to assess the impact of EGFR-targeted therapies on clinical outcomes in patients with HER2-positive metastatic colorectal cancer.

FDA Grants Priority Review to Tucatinib/Trastuzumab Combo for Previously Treated HER2+ mCRC

September 19th 2022

The FDA has granted a priority review to a supplemental new drug application seeking the approval of tucatinib for use in combination with trastuzumab in adult patients with HER2-positive colorectal cancer who have received at least 1 prior treatment regimen for unresectable or metastatic disease.

Dose-Optimized Regorafenib Leads to Improved Survival in mCRC

September 16th 2022

Dose optimization of regorafenib led to improved survival outcomes compared with best supportive care of fruquintinib, standard-dose regorafenib, and trifluridine/tipiracil in patients with relapsed/refractory metastatic colorectal cancer.